Cargando…
Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path
Background: Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient’s sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911172/ https://www.ncbi.nlm.nih.gov/pubmed/33499332 http://dx.doi.org/10.3390/brainsci11020146 |
_version_ | 1783656278756687872 |
---|---|
author | Wieckiewicz, Mieszko Martynowicz, Helena Wieczorek, Tomasz Wojakowska, Anna Sluzalec-Wieckiewicz, Katarzyna Gac, Pawel Poreba, Rafal Mazur, Grzegorz Winocur, Efraim Smardz, Joanna |
author_facet | Wieckiewicz, Mieszko Martynowicz, Helena Wieczorek, Tomasz Wojakowska, Anna Sluzalec-Wieckiewicz, Katarzyna Gac, Pawel Poreba, Rafal Mazur, Grzegorz Winocur, Efraim Smardz, Joanna |
author_sort | Wieckiewicz, Mieszko |
collection | PubMed |
description | Background: Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient’s sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypical TCA, as it acts primarily as a sigma receptor agonist. This study aimed to preliminarily determine the effectiveness of opipramol in the management of severe SB. Methods: A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were then analyzed by control stage II vPSG. Results: The participants included 14 females and 5 males, aged 20–47 years (mean ± standard deviation: 32.32 ± 8.12). A comparison of stage I and II vPSG recordings showed a decrease in all the studied SB parameters in 78.85% of participants. Only in a small group of participants (15.53%) was a non-significant increase of SB parameters observed. Conclusions: A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group. |
format | Online Article Text |
id | pubmed-7911172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79111722021-02-28 Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path Wieckiewicz, Mieszko Martynowicz, Helena Wieczorek, Tomasz Wojakowska, Anna Sluzalec-Wieckiewicz, Katarzyna Gac, Pawel Poreba, Rafal Mazur, Grzegorz Winocur, Efraim Smardz, Joanna Brain Sci Article Background: Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient’s sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypical TCA, as it acts primarily as a sigma receptor agonist. This study aimed to preliminarily determine the effectiveness of opipramol in the management of severe SB. Methods: A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were then analyzed by control stage II vPSG. Results: The participants included 14 females and 5 males, aged 20–47 years (mean ± standard deviation: 32.32 ± 8.12). A comparison of stage I and II vPSG recordings showed a decrease in all the studied SB parameters in 78.85% of participants. Only in a small group of participants (15.53%) was a non-significant increase of SB parameters observed. Conclusions: A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group. MDPI 2021-01-22 /pmc/articles/PMC7911172/ /pubmed/33499332 http://dx.doi.org/10.3390/brainsci11020146 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wieckiewicz, Mieszko Martynowicz, Helena Wieczorek, Tomasz Wojakowska, Anna Sluzalec-Wieckiewicz, Katarzyna Gac, Pawel Poreba, Rafal Mazur, Grzegorz Winocur, Efraim Smardz, Joanna Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title | Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title_full | Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title_fullStr | Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title_full_unstemmed | Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title_short | Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management—Preliminary Study on New Therapeutic Path |
title_sort | consecutive controlled case series on effectiveness of opipramol in severe sleep bruxism management—preliminary study on new therapeutic path |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911172/ https://www.ncbi.nlm.nih.gov/pubmed/33499332 http://dx.doi.org/10.3390/brainsci11020146 |
work_keys_str_mv | AT wieckiewiczmieszko consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT martynowiczhelena consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT wieczorektomasz consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT wojakowskaanna consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT sluzalecwieckiewiczkatarzyna consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT gacpawel consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT porebarafal consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT mazurgrzegorz consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT winocurefraim consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath AT smardzjoanna consecutivecontrolledcaseseriesoneffectivenessofopipramolinseveresleepbruxismmanagementpreliminarystudyonnewtherapeuticpath |